Valuation: NEOVACS SA

Market Cap 4.09K 4.63K 3.87K 3.51K 6.58K 445K 6.64K 46.41K 17.89K 227K 17.4K 17.02K 731K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -228K -190K -172K -323K -21.85M -327K -2.28M -879K -11.16M -855K -837K -35.91M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 28/05/2003
Director/Board Member - 01/05/2020
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 41.49K
-0.03%+3.77%+12.35%+37.22% 49.06B
-0.48%-0.11%+49.29%+37.13% 44.6B
+1.23%+5.57%+341.95%+635.57% 43.24B
+0.11%-0.64%+9.88%+103.32% 41.73B
+0.34%-1.38%+5.53%+47.36% 29.93B
+0.93%-1.57%+23.88%+156.19% 17.19B
-3.42%+7.20%+5.31% - 15.35B
-3.20%-2.38%+25.00%+43.67% 15.54B
-0.69%-3.62% - - 15.11B
Average -0.63%+1.68%+59.15%+151.49% 30.19B
Weighted average by Cap. -0.26%+2.13%+74.22%+166.01%

Financials

2023 2024
Net sales 533K 604K 505K 458K 858K 58M 867K 6.05M 2.33M 29.62M 2.27M 2.22M 95.31M 434K 492K 411K 372K 698K 47.18M 705K 4.93M 1.9M 24.09M 1.85M 1.81M 77.53M
Net income -8.74M -9.91M -8.27M -7.5M -14.07M -951M -14.2M -99.24M -38.25M -485M -37.2M -36.39M -1.56B -32.91M -37.3M -31.14M -28.24M -52.95M -3.58B -53.47M -374M -144M -1.83B -140M -137M -5.88B
Net Debt -237K -268K -224K -203K -380K -25.72M -384K -2.68M -1.03M -13.13M -1.01M -984K -42.26M -205K -232K -194K -176K -330K -22.3M -333K -2.33M -897K -11.39M -873K -854K -36.64M
Logo NEOVACS SA
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
-